Back to UBS Group AG UBS Group AG

PLXPLX
Showing 8 of 27 quarters

Position history for UBS Group AGUBS Group AG's holdings in PROTALIX BIOTHERAPEUTICS INC

UBS Group AG holds 138,646 shares of PLX (PROTALIX BIOTHERAPEUTICS INC), worth $323,045 as of 2026-Q2. The position was decreased (-47.8% shares).

Current Value

$323,045

Current Shares

138,646

Total Value Change

+$322,747

Total Shares Change

+138,354

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
138,646
-47.8%
$323,0450.0%$2.33
0
2026-Q1
Increased
265,535
+1.1%
$576,2110.0%$2.83
25
2025-Q4
Increased
262,520
+38.0%
$472,5360.0%$1.74
32
2025-Q3
Increased
190,276
+153.2%
$422,4130.0%$2.16
39
2025-Q2
Increased
75,150
+3500.9%
$111,2220.0%$1.54
24
2025-Q1
Decreased
2,087
-88.5%
$5,3430.0%$2.58
0
2024-Q4
Increased
18,178
+6125.3%
$34,1750.0%$1.89
22
2024-Q3
Decreased
292
-4.9%
$2980.0%$1.05
0

Other major holders of PLX: BlackRock, Inc., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used